GoodRx Holdings, Inc. (GDRX) Financial Ratio Screen
Track GDRX screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
GDRX financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Health Information Services) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: SEC filing extraction found 4 dimensioned facts; 0 have passed extraction review. No activity conclusion is made. Open the SEC annual filing.
View SEC-extracted business segments
- Prescription Transactions Revenue — 68.3% of filing total · extraction pending
- Pharma Direct Revenue — 19.0% of filing total · extraction pending
- Subscription Revenue — 10.5% of filing total · extraction pending
- Other Revenue — 2.2% of filing total · extraction pending
Profile description reviewed: GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 38.7% / 30% | 18.6% / 30% | 36.8% / 30% | 1.37% / 5% | RATIOS FAIL* |
| S&P-style (provisional) | 28.6% / 33% | N/A | N/A | 1.37% / 5% | FINANCIAL SCREEN PASSED* |
| FTSE | 38.7% / 33% | 18.6% / 33% | 36.8% / 50% | 1.37% / 5% | RATIOS FAIL* |
Financial Highlights
Profitability
| Gross Margin | 90.8% | |
| Operating Margin | 11.8% | |
| Net Margin | 2.1% | |
| Return on Equity (ROE) | 2.5% | |
| Return on Assets (ROA) | 3.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $168M |
| Free Cash Flow | $94M |
| Total Debt | $543M |
| Debt-to-Equity | 83.2 |
| Current Ratio | 1.4 |
| Total Assets | $1.4B |
Price & Trading
| Last Close | $3.56 |
| 50-Day MA | $3.12 |
| 200-Day MA | $2.67 |
| Avg Volume | 1.5M |
| Beta | 1.6 |
|
52-Week Range
$1.77
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-08-24 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Historical market-cap evidence
37 monthly estimates are retained from
2023-07-31 to
2026-07-31. Each point combines a
month-end close from
Nasdaq public historical endpoint
with an SEC-reported share count. The
latest share evidence is dated
2026-03-31
(10-Q,
tag us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,
accession 0001809519-26-000111).
Open SEC XBRL evidence.
Open Nasdaq price evidence.
When 36 completed months are available, these observations support
a provisional independent S&P-style leverage calculation.
This reconstruction is not official S&P index data, does not prove
index membership, and does not complete the separate activity-income
screen. DJIM remains unavailable.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About GoodRx Holdings, Inc. (GDRX)
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is GoodRx Holdings, Inc. (GDRX) halal to invest in?
The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is GoodRx Holdings, Inc.'s debt ratio?
GoodRx Holdings, Inc.'s debt ratio is 38.7% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are GoodRx Holdings, Inc.'s key financial metrics?
GoodRx Holdings, Inc. has a market capitalization of USD 1177M in its listing currency, trailing P/E ratio of 57.5, and revenue of $797M. The company maintains a gross margin of 90.8% and a net margin of 2.1%. Return on equity stands at 2.5%.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.